Paget’s Disease Mimicking Prostate Cancer Metastasis with <sup>68</sup>Ga-PSMA PET/CT
PDF
Cite
Share
Request
Interesting Image
P: 199-202
October 2024

Paget’s Disease Mimicking Prostate Cancer Metastasis with 68Ga-PSMA PET/CT

Mol Imaging Radionucl Ther 2024;33(3):199-202
1. İstanbul University İstanbul Faculty of Medicine, Department of Nuclear Medicine, İstanbul, Türkiye
No information available.
No information available
Received Date: 07.09.2023
Accepted Date: 25.03.2024
Online Date: 07.10.2024
Publish Date: 07.10.2024
PDF
Cite
Share
Request

Abstract

68Ga-prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography imaging successfully detects bone metastases in prostate cancer (PCa). However, assuming that all detected PSMA-avid bone lesions are metastases should be avoided. It is essential to evaluate PCa patients with clinical findings and to consider possible differential diagnoses, especially in low-risk patients. Herein, we present the case of a 62-year-old male patient recently diagnosed with low-risk prostate adenocarcinoma with a PSMA-avid bone lesion corresponding to Paget’s disease.

References

1
Simsek DH, Sanli Y, Civan C, Engin MN, Isik EG, Ozkan ZG, Kuyumcu S. Does bone scintigraphy still have a role in the era of 68 Ga-PSMA PET/CT in prostate cancer? Ann Nucl Med. 2020;34:476-485.
2
Pomykala KL, Czernin J, Grogan TR, Armstrong WR, Williams J, Calais J. Total-Body 68Ga-PSMA-11 PET/CT for Bone Metastasis Detection in Prostate Cancer Patients: Potential Impact on Bone Scan Guidelines. J Nucl Med. 2020;61:405-411.
3
Bourgeois S, Gykiere P, Goethals L, Everaert H, De Geeter FW. Aspecific Uptake of 68GA-PSMA in Paget Disease of the Bone. Clin Nucl Med. 2016;41:877-878.
4
Sasikumar A, Joy A, Nanabala R, Pillai MR, T A H. 68Ga-PSMA PET/CT False-Positive Tracer Uptake in Paget Disease. Clin Nucl Med. 2016;41:e454-e455.
5
de Galiza Barbosa F, Queiroz MA, Nunes RF, Costa LB, Zaniboni EC, Marin JFG, Cerri GG, Buchpiguel CA. Nonprostatic diseases on PSMA PET imaging: a spectrum of benign and malignant findings. Cancer Imaging. 2020;20:23.
6
Malik D, Kumar R, Mittal BR, Singh H, Bhattacharya A, Singh SK. 68Ga-Labeled PSMA Uptake in Nonprostatic Malignancies: Has the Time Come to Remove “PS” From PSMA? Clin Nucl Med. 2018;43:529-532.
7
Ralston SH, Corral-Gudino L, Cooper C, Francis RM, Fraser WD, Gennari L, Guañabens N, Javaid MK, Layfield R, O’Neill TW, Russell RGG, Stone MD, Simpson K, Wilkinson D, Wills R, Zillikens MC, Tuck SP. Diagnosis and Management of Paget’s Disease of Bone in Adults: A Clinical Guideline. J Bone Miner Res. 2019;34:579-604.
8
Willemse PM, Davis NF, Grivas N, Zattoni F, Lardas M, Briers E, Cumberbatch MG, De Santis M, Dell’Oglio P, Donaldson JF, Fossati N, Gandaglia G, Gillessen S, Grummet JP, Henry AM, Liew M, MacLennan S, Mason MD, Moris L, Plass K, O’Hanlon S, Omar MI, Oprea-Lager DE, Pang KH, Paterson CC, Ploussard G, Rouvière O, Schoots IG, Tilki D, van den Bergh RCN, Van den Broeck T, van der Kwast TH, van der Poel HG, Wiegel T, Yuan CY, Cornford P, Mottet N, Lam TBL. Systematic Review of Active Surveillance for Clinically Localised Prostate Cancer to Develop Recommendations Regarding Inclusion of Intermediate-risk Disease, Biopsy Characteristics at Inclusion and Monitoring, and Surveillance Repeat Biopsy Strategy. Eur Urol. 2022;81:337-346.